DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients

Information source: AHS Cancer Control Alberta
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cancer; Pain

Intervention: Sublingual Methadone (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Alberta Health Services

Official(s) and/or principal investigator(s):
Neil Hagen, MD, Principal Investigator, Affiliation: AHS Cancer Control Alberta


The purpose of this Phase II study is to determine the feasibility of the dose titration and assessment protocol in the outpatient population before conducting an appropriately powered phase III study. Thus the primary purpose of this study is to determine the proportion of patients who are successfully titrated to an optimal dose of sublingual (Under the tongue) methadone and then studied at that optimal dose with successive episodes of breakthrough pain.

Clinical Details

Official title: Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients: a Phase II Multicenter, Open Label, Feasibility Study

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: to demonstrate the feasibility of a novel model to assess sublingual methadone to breakthrough pain in the outpatient setting

Secondary outcome:

to develop a model of PK/PD study of breakthrough pain

to develop a research tool, the Breakthrough Pain Assessment Tool (BPAT)

to demonstrate proof of concept


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Pain due to cancer or its treatment; controlled baseline pain;

- episodes of breakthrough pain every day that are "4/10" in severity or greater, ;

- ast 10 minutes or longer, and

- are responsive to short acting oral opioids such as morphine or hydromorphone;

- are able to hole a volume of 1. 0cc of water under the tongue for a 5-minute period;

are able to provide written informed consent;

- are able to fill out the study forms

Exclusion Criteria:

- Severe underlying respiratory disease such that an investigator is wary about the

risk of respiratory failure from modest doses of opioid;

- prior sensitivity to methadone;

- currently are being administered methadone;

- have breakthrough pain that in the opinion of the investigator is likely to change

within the next seven days (recent or imminent radiation therapy to the main site of pain,

- new chemotherapy or use of an injectable bisphosphonate likely to alter the pain, new

use corticosteroids within the past week with a corresponding change in pain, or other interventions judged likely to alter pain);

- are clinically unstable or have a life expectancy of less than one month making

completion of the trial unlikely

Locations and Contacts

Tom Baker Cancer Center, Calgary, Alberta T2N 4N2, Canada

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Additional Information

Starting date: July 2008
Last updated: January 24, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017